Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02462083 · ClinicalTrials.gov registry record · Phase 3
Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis
A Phase 3 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 3
- Development phase
- 555
- Enrollment target
NCT02462083: Completed Phase 3 study, sponsored by Bausch Health Americas.
NCT02462083 is a Phase 3 study that has completed, run by Bausch Health Americas. The registered enrollment target is 555 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (28% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02462083, a Phase 3 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 555 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the long-term safety of IDP-118 lotion.
Primary Outcome
Local skin reactions (itching, dryness, burning/stinging) graded at a level of 3 (severe) at any point in the study following the first application of study drug were assessed. Severe Itching (as reported by the participant within the last 24 hours) referred to the intense itching that may interrupt daily activities and/or sleep. Severe dryness (as assessed by the investigator) referred to as marked roughness of the skin. Severe burning/stinging (as reported by the participant within the last 24
Interventions
- DRUG IDP-118 Lotion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 555 participants |
| Start Date | 2015-08-11 |
| Est. Completion | 2017-04-24 |
| Phase | Phase 3 |
What the finished NCT02462083 record still lists
NCT02462083 is an interventional study that assigns participants to a tested intervention. The registered 555 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (28% lower).
The record links to 0 conditions, and to 1 intervention - of which IDP-118 Lotion is the first listed.
NCT02462083 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02462083 about?
NCT02462083 is a clinical study titled "Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis". The objective of this study is to evaluate the long-term safety of IDP-118 lotion.
What is the current status of trial NCT02462083?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 555 participants. The study started on 2015-08-11. Estimated completion is 2017-04-24.
What interventions are being tested in trial NCT02462083?
The interventions under investigation include: IDP-118 Lotion (DRUG).
Who is sponsoring clinical trial NCT02462083?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02462083's enrollment target sits among peer trials
555 676th of 2000 higher than 1,323 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06799000 · 555 participants · Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
- NCT06840392 · 555 participants · Phase 3
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
- NCT06074588 · 556 participants · Phase 3
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
- NCT06693622 · 556 participants
Patient Preferences for Barrett's Esophagus and Esophageal Cancer Screening Tests
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI